Version 1
: Received: 3 February 2020 / Approved: 4 February 2020 / Online: 4 February 2020 (10:59:25 CET)
How to cite:
Cui, Q.; Huang, C.; Ji, X.; Zhang, W.; Zhang, F.; Wang, L. Possible Inhibitors of ACE2, the Receptor of 2019-nCoV. Preprints2020, 2020020047. https://doi.org/10.20944/preprints202002.0047.v1
Cui, Q.; Huang, C.; Ji, X.; Zhang, W.; Zhang, F.; Wang, L. Possible Inhibitors of ACE2, the Receptor of 2019-nCoV. Preprints 2020, 2020020047. https://doi.org/10.20944/preprints202002.0047.v1
Cui, Q.; Huang, C.; Ji, X.; Zhang, W.; Zhang, F.; Wang, L. Possible Inhibitors of ACE2, the Receptor of 2019-nCoV. Preprints2020, 2020020047. https://doi.org/10.20944/preprints202002.0047.v1
APA Style
Cui, Q., Huang, C., Ji, X., Zhang, W., Zhang, F., & Wang, L. (2020). Possible Inhibitors of ACE2, the Receptor of 2019-nCoV. Preprints. https://doi.org/10.20944/preprints202002.0047.v1
Chicago/Turabian Style
Cui, Q., Fenghong Zhang and Liang Wang. 2020 "Possible Inhibitors of ACE2, the Receptor of 2019-nCoV" Preprints. https://doi.org/10.20944/preprints202002.0047.v1
Abstract
Most recently, an outbreak of severe pneumonia caused by the infection of 2019-nCoV, a novel coronavirus first identified in Wuhan, China, imposes serious threats to public health. Many important aspects about 2019-nCoV remain largely unknown, among which, the limitation of antiviral therapies represents one of the most critical problems. More recently, it was confirmed that human ACE2 is the receptor for the entry of 2019-nCoV into lower respiratory tract epithelial cells. Give this observation, it is thus expected that the virus could be inhibited if we decrease the expression of ACE2. Here by screening two databases, Connectivity Map (CMap) and our JeaMoon Map (JMap), we identified a number of candidate agents that decrease ACE2 expression. CMap analysis identified 5 compounds, among which, Azathioprine is a possible therapeutic strategy for anti-2019-nCoV. Moreover, JMap analysis revealed a number of comounds, biologics, and traditional Chinese medicine, among which, Andrographis, Urtica, Sambucus, Astragalus, valproic acid, butyrate, and epoxomicin represent the most significant and possible strategies for anti-2019-nCoV therapies. This study provides a number of clues and possible therapeutic strategies for 2019-nCoV prevention and treatment.
Keywords
2019-nCoV; therapeutic strategies; drug; ACE2
Subject
Medicine and Pharmacology, Pharmacology and Toxicology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
